BTG.L - BTG plc

LSE - LSE Delayed Price. Currency in GBp
835.00
0.00 (0.00%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close835.00
Open835.00
Bid834.50 x 66000
Ask835.00 x 112600
Day's Range834.00 - 835.00
52 Week Range467.40 - 853.00
Volume417,130
Avg. Volume943,543
Market Cap3.241B
Beta (3Y Monthly)-0.11
PE Ratio (TTM)114.38
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1998-07-13
1y Target EstN/A
All
News
Press Releases
  • Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing
    PR Newswire2 months ago

    Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing

    BOTHELL, WA , April 29, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), the global specialist healthcare company, today highlighted the VIEW VLU Registry interim study results, presented at the International ...

  • Business Wire2 months ago

    Trial Finds Patients Receiving CroFab® Antivenom Less Likely to Use Opioids for Pain Control

    BTG plc (BTG.L), the global healthcare company, today announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine (WestJEM). “In a randomized, double-blind, placebo-controlled, clinical trial of CroFab® for treatment of copperhead snakebite, patients that received CroFab® were less likely to use opioids for pain control during recovery,” said Dr. Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in copperhead snake envenomation.

  • PR Newswire4 months ago

    NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients With Metastatic Disease

    LONDON , Feb. 5, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019 ...

  • PR Newswire5 months ago

    Australian Patient Treated With DC Bead LUMI™, the First Commercially Available Radiopaque Drug-Eluting Bead

    LONDON , January 21, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development ...

  • PR Newswire5 months ago

    BTG and OMNY Partner to Improve Treatment of Snake Bite Victims

    BTG, the global healthcare company, is partnering with OMNY to improve visibility of inventory data for its antivenom product CroFab® using distributed ledger technology. This makes it important to understand and manage antivenom stock levels. CroFab® is the only FDA-approved product to treat all North American pit viper envenomations in adult and pediatric patients.[ii],[iii] It is proven to control local, systemic, and hematologic effects of envenomation[ii], [iv], * and 95% of patients showed a clinical response 1 hour after initial control[v].

  • PR Newswire6 months ago

    BTG Announces National Reimbursement for TheraSphere® in France

    BTG plc (BTG.L), a global specialist healthcare company, today announced that the French Ministry of Health and Social Affairs will reimburse TheraSphere® for patients with liver cancer who meet certain criteria. "This reimbursement decision provides access to a new treatment option for some of the estimated 9,600 people diagnosed with liver cancer in France each year[iv]," said Jane Lapon, VP Global Market Access at BTG.

  • Business Wire6 months ago

    Arizona Patients Successfully Receive the World’s First Bioconvertible IVC Filter Commercially Offered In US

    BTG plc (BTG.L), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter. The BTG Sentry filter is designed to provide protection from Pulmonary Embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, eliminating the need to retrieve and addressing the typical filter-related complications associated with conventional IVC filters. Dr. Ayad K.M. Agha, Director of Interventional Radiology and an interventional radiologist at Cardiovascular Interventional Radiology Centers in Phoenix, Arizona, who performed the procedure on one of his patients, said: “Traditional IVC filters are sometimes associated with a variety of concerns.

  • PR Newswire7 months ago

    Boston Scientific Announces Recommended Offer to Acquire BTG plc.

    The transaction has been unanimously approved by the boards of directors of Boston Scientific and BTG. Under the terms of the transaction, holders of BTG's common shares would receive cash consideration of 840 pence per share. The total cash consideration for 100% of BTG's equity is approximately £3.3B, or U.S.$4.2B.

  • Business Wire7 months ago

    BTG Sentry Bioconvertible IVC Filter 2-year Study Results Show Zero Tilt, Migration, Perforation, Fracture, or Embolization

    BTG plc (BTG.L), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances (VIVA) conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, the world’s first bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism (PE) during the transient risk period, the device also had zero instances of tilt, perforation, migration and embolization through two years of imaging-intensive follow-up. “This long-term data marks a paradigm shift in pulmonary embolism protection and is exactly why we brought the BTG Sentry to market,” said BTG Chief Commercial Officer John Sylvester.

  • Business Wire7 months ago

    EKOS™ Control Unit 4.0 Simplifies Treatment of Blood Clots

    First commercial units are shipped to Europe

  • PR Newswire8 months ago

    Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman

    Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has today announced that it has licensed exclusive worldwide rights to develop and commercialise BTG945, now CT900, an investigational targeted ovarian cancer drug, from the global specialist healthcare company BTG plc ("BTG", LSE: BTG). CT900 is a targeted therapy that combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase.

  • PR Newswire9 months ago

    BTG Announces Replacement Policy for Expired CroFab®

    WEST CONSHOHOCKEN, Pa. , Sept. 26, 2018 /PRNewswire/ --   BTG plc (LSE: BTG) today announced a policy for replacement of expired vials of CroFab ® Crotalidae Polyvalent Immune Fab (Ovine), allowing customers ...

  • PR Newswire9 months ago

    BTG Announces Global Launch of the ICEfx™ Cryoablation System

    LONDON , September 20, 2018 /PRNewswire/ -- The ICEfx™ Cryoablation system is a compact and powerful console, offering predictable, reliable performance with seamless therapy delivery and exceptional ease ...

  • PR Newswire9 months ago

    FDA Approves CroFab® Product Improvements

    Updated label describes extended shelf life and removal of mercury WEST CONSHOHOCKEN, Pa. , Sept. 13, 2018 /PRNewswire/ -- BTG plc (LSE: BTG) announced that the US Food & Drug Administration (FDA) has ...

  • Business Wire9 months ago

    BTG plc acquires Novate Medical Ltd.

    BTG plc (BTG.L), the global specialist healthcare company, today announces it has acquired Novate Medical Ltd. (“Novate”), a medical device company focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events. Novate has developed Sentry, the first bioconvertible inferior vena cava (IVC) filter, which has recently been granted 510(k) regulatory clearance in the US.

  • Business Wire11 months ago

    OPTALYSE PE Results Published in JACC: Cardiovascular Interventions

    BTG plc , the global healthcare company, highlighted the publication of OPTALYSE PE trial results in JACC: Cardiovascular Interventions. The published findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with EKOSⓇ Acoustic Pulse Thrombolysis™ therapy shows significant improvement in RV/LV ratio and with a very low one-year mortality rate of 2% and an equally low ...

  • Business Wirelast year

    PERT Consortium and BTG Form Strategic Partnership

    BTG plc (BTG.L), the global healthcare company, today announced at the annual PERT ConsortiumTM Meeting in Nashville, TN, a strategic partnership with the PERT ConsortiumTM to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERTTM programs across the U.S. In the United States, pulmonary embolism afflicts 500,000–600,000 patients annually1,2 and is either a primary or secondary cause of death in 150,000–200,000 of these individuals2. In their new partnership, BTG and the PERT ConsortiumTM are uniting to address this disease via expanding options for professional education, expanding clinical research, establishing quality benchmarks for care of PE, and developing new mobile technologies to convene PERT teams and improve decision-making.